Last reviewed 2026-04-23 · How we verify

ELGN-2112

Elgan Pharma Ltd. · Phase 3 active Small molecule

ELGN-2112 is a SGLT2 inhibitor Small molecule drug developed by Elgan Pharma Ltd.. It is currently in Phase 3 development for Type 2 diabetes.

ELGN-2112 is a small molecule that targets the SGLT2 receptor.

ELGN-2112 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.

Likelihood of approval

58.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ELGN-2112
Sponsor	Elgan Pharma Ltd.
Drug class	SGLT2 inhibitor
Target	SGLT2
Modality	Small molecule
Therapeutic area	Diabetes
Phase	Phase 3

Mechanism of action

By inhibiting SGLT2, ELGN-2112 reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is particularly useful in the treatment of type 2 diabetes.

Approved indications

Type 2 diabetes

Common side effects

Increased risk of genital yeast infections

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ELGN-2112 CI brief — competitive landscape report
ELGN-2112 updates RSS · CI watch RSS
Elgan Pharma Ltd. portfolio CI

Frequently asked questions about ELGN-2112

What is ELGN-2112?

ELGN-2112 is a SGLT2 inhibitor drug developed by Elgan Pharma Ltd., indicated for Type 2 diabetes.

How does ELGN-2112 work?

ELGN-2112 is a small molecule that targets the SGLT2 receptor.

What is ELGN-2112 used for?

ELGN-2112 is indicated for Type 2 diabetes.

Who makes ELGN-2112?

ELGN-2112 is developed by Elgan Pharma Ltd. (see full Elgan Pharma Ltd. pipeline at /company/elgan-pharma-ltd).

What drug class is ELGN-2112 in?

ELGN-2112 belongs to the SGLT2 inhibitor class. See all SGLT2 inhibitor drugs at /class/sglt2-inhibitor.

What development phase is ELGN-2112 in?

ELGN-2112 is in Phase 3.

What are the side effects of ELGN-2112?

Common side effects of ELGN-2112 include Increased risk of genital yeast infections.

What does ELGN-2112 target?

ELGN-2112 targets SGLT2 and is a SGLT2 inhibitor.

Drug class: All SGLT2 inhibitor drugs
Target: All drugs targeting SGLT2
Manufacturer: Elgan Pharma Ltd. — full pipeline
Therapeutic area: All drugs in Diabetes
Indication: Drugs for Type 2 diabetes

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing